Cathodal Transcranial Direct Current Stimulation in Patients With Drug-resistant Focal Epilepsy

NCT ID: NCT05951244

Last Updated: 2023-07-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-03

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The basis of this project is the application of cathodal tDCS in patients with drug-resistant focal epilepsy including patients whose seizures persist after epilepsy surgery, who rejected epilepsy surgery, and/or who are not suitable for surgery. For this purpose, 5-day consecutive cathodal electrical stimulation sessions will be used with personalized electrode montage according to the patient's seizure focus. In this context, the changes in seizures frequency and epileptic discharges will be examined for the first week and 12th week after the tDCS sessions through the seizure diary of the patients and the electroencephalogram (EEG) recordings to be taken. In addition, changes in cognitive functions, mood, and quality of life will be examined in patients after the intervention.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Resistant Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transcranial Direct Stimulation

20 epilepsy patients who were eligible and gave consent according to the inclusion criteria. For active group, tDCS treatment will be 2 mA current strength for 30 minutes.

Group Type ACTIVE_COMPARATOR

Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)

Intervention Type DEVICE

Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.

Sham-Transcranial Direct Current Stimulation

20 epilepsy patients who were eligible and gave consent according to the inclusion criteria.

For the sham group, the current will increase to 2mA in 10 seconds, continue for the 30s, then decrease to 0 in 10 seconds and cut off.

Group Type SHAM_COMPARATOR

Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)

Intervention Type DEVICE

Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)

Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years and older,
* Diagnosed with focal epilepsy with epileptic focus determined according to clinical and electroencephalogram recordings, who have undergone epilepsy surgery but seizures persist, who refuse epilepsy surgery or who are considered unsuitable for surgery,
* Patients who comply with the definition of drug-resistant epilepsy according to ILAE (International League Against Epilepsy Classification) criteria (Patients who have failed to achieve long-term seizure-free status despite at least two appropriate antiepileptic drugs given alone or in combination),
* Minimum 1 or more seizures per month (minimum 3 months),
* No antiepileptic dose change until 3 weeks before the study, stable treatment, and no dose change planned during the study,
* At least 1.5 Tesla MR imaging was performed before the study,
* Signed the informed consent form or the consent form signed by the legal representative,
* EEG was present before the study and all EEG data was accessible,
* Cooperative patients who can speak, understand and communicate in Turkish will be recruited.

Exclusion Criteria

* The presence of any disease/deformity in the patient that the researchers believe will affect the patient's safety or the reliability of the data to be collected,
* Detection of more than one seizure focus in the patient,
* The patient had a psychogenic non-epileptic seizure attack (Psychogenic Non-epileptic Seizures -PNES) within 2 years prior to the study,
* Having a generalized onset seizure,
* Having had status epilepticus in the last 1 year,
* Presence of any disease, medical condition, or physical condition that, according to the researchers, could prevent, limit, affect or reduce the subject's completion of a minimum period of 1 + 12 weeks,
* Tissue damage (eczema, etc.) in the area where tDCS will be applied on the skin,
* Patients who are pregnant and do not use/do not want to use contraception during the study period,
* Lactating women,
* Metal implants, fillings in the head or teeth, presence of a medical device in the body (pacemaker, deep brain stimulator, cochlear implant, nerve stimulator, etc.)
* Presence of a skull defect with a radius of 5 mm and/or larger remaining from previous surgeries,
* The patient is participating in another clinical trial.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Koç University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ezgi Tuna Erdoğan, Assist Prof.

Role: PRINCIPAL_INVESTIGATOR

Koç University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Koc University

Istanbul, Sarıyer, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ezgi Tuna Erdoğan, Assist Prof.

Role: CONTACT

+90 533 643 4749

Sacit Karamürsel, Professor

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Candan Gürses

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NM002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Transcranial Direct Current to Treat Epilepsy at Home
NCT04309812 ENROLLING_BY_INVITATION EARLY_PHASE1
Electrical Neuromodulation for Focal Epilepsy
NCT05844696 UNKNOWN PHASE1/PHASE2
Thermocoagulation in Drug Resistant Focal Epilepsy
NCT05248269 ACTIVE_NOT_RECRUITING NA